Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis

verfasst von: Dong-Tao Shi, Mei Han, Nan Gao, Wenyan Tian, Weichang Chen

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Ras-association domain family 1A (RASSF1A), a candidate tumor suppressor gene, is frequently silenced and inactivated by hypermethylation of its promoter region in several human tumors. However, the association between RASSF1A promoter methylation and gastric cancer risk remains conflicting. The aim of this study was to assess the association of RASSF1A promoter methylation with gastric cancer risk by a comprehensive meta-analysis. Relevant studies were identified by searches of PubMed and Web of Science databases with no restrictions. Combined odds ratio (OR) and 95 % confidence interval (CI) were used to assess the strength of the association between RASSF1A promoter methylation and gastric cancer risk. A chi-square-based Q test and sensitivity analyses were performed to test the between-study heterogeneity and the contributions of single studies to the final results, respectively. Funnel plots were carried out to evaluate publication bias. Overall, a significant association was observed between RASSF1A promoter methylation and gastric cancer risk (OR, 12.67; 95 % CI, 8.12–19.78; p < 0.001) with no between-study heterogeneity. Subgroup analyses further revealed that gastric cancer risk was increased for individuals carrying the methylated RASSF1A compared with those with unmethylated RASSF1A. In addition, no publication bias was detected in the overall and subgroup analyses. This study identified a strong association between RASSF1A promoter methylation and risk of gastric cancer and highlighted a promising potential for RASSF1A promoter methylation in gastric cancer risk prediction.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9.PubMedCrossRef Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9.PubMedCrossRef
3.
Zurück zum Zitat Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer. 2002;5:6–15.PubMedCrossRef Kikuchi S. Epidemiology of Helicobacter pylori and gastric cancer. Gastric Cancer. 2002;5:6–15.PubMedCrossRef
4.
Zurück zum Zitat Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49–95.PubMedCrossRef Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49–95.PubMedCrossRef
5.
Zurück zum Zitat Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol. 2002;17:323–9.PubMed Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol. 2002;17:323–9.PubMed
6.
7.
Zurück zum Zitat Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4:279–94.PubMedCrossRef Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4:279–94.PubMedCrossRef
8.
Zurück zum Zitat Agathanggelou A, Cooper WN, Latif F. Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497–508.PubMedCrossRef Agathanggelou A, Cooper WN, Latif F. Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497–508.PubMedCrossRef
9.
Zurück zum Zitat Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the rassf1a gene in human cancers. Biol Chem. 2002;383:907–14.PubMedCrossRef Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the rassf1a gene in human cancers. Biol Chem. 2002;383:907–14.PubMedCrossRef
10.
Zurück zum Zitat Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baler K, et al. The tumor suppressor rassf1a in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–63.PubMed Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baler K, et al. The tumor suppressor rassf1a in human carcinogenesis: an update. Histol Histopathol. 2005;20:645–63.PubMed
11.
Zurück zum Zitat Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a ras association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–9.PubMedCrossRef Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a ras association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–9.PubMedCrossRef
13.
Zurück zum Zitat Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of rassf1a by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001;61:7034–8.PubMed Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of rassf1a by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001;61:7034–8.PubMed
14.
Zurück zum Zitat To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer. 2002;102:623–8.PubMedCrossRef To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer. 2002;102:623–8.PubMedCrossRef
15.
Zurück zum Zitat Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, Boutron-Ruault MC, et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European prospective investigation into cancer and nutrition (epic-eurgast). Cancer Lett. 2011;311:85–95.PubMedCrossRef Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, Boutron-Ruault MC, et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European prospective investigation into cancer and nutrition (epic-eurgast). Cancer Lett. 2011;311:85–95.PubMedCrossRef
16.
Zurück zum Zitat Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–76.PubMed Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–76.PubMed
17.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
18.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
19.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
20.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
21.
Zurück zum Zitat Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant cpg island methylation along the multistep pathway of gastric carcinogenesis. Lab Investig. 2003;83:635–41.PubMedCrossRef Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant cpg island methylation along the multistep pathway of gastric carcinogenesis. Lab Investig. 2003;83:635–41.PubMedCrossRef
22.
Zurück zum Zitat Ye M, Xia B, Guo QS, Zhou F, Zhang XL. [The influence of promoter methylation of rassf1a on rassf1a mrna and protein expression in gastric cancer tissues]. Zhonghua Nei Ke Za Zhi. 2006;45:1008–12.PubMed Ye M, Xia B, Guo QS, Zhou F, Zhang XL. [The influence of promoter methylation of rassf1a on rassf1a mrna and protein expression in gastric cancer tissues]. Zhonghua Nei Ke Za Zhi. 2006;45:1008–12.PubMed
23.
Zurück zum Zitat Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant cpg island methylation along multistep gastric carcinogenesis. Lab Investig. 2003;83:519–26.PubMedCrossRef Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant cpg island methylation along multistep gastric carcinogenesis. Lab Investig. 2003;83:519–26.PubMedCrossRef
24.
Zurück zum Zitat Ye M, Xia B, Guo Q, Zhou F, Zhang X. Association of diminished expression of rassf1a with promoter methylation in primary gastric cancer from patients of central china. BMC Cancer. 2007;7:120.PubMedCentralPubMedCrossRef Ye M, Xia B, Guo Q, Zhou F, Zhang X. Association of diminished expression of rassf1a with promoter methylation in primary gastric cancer from patients of central china. BMC Cancer. 2007;7:120.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of rassf1a promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008;14:3074–80.PubMedCrossRef Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of rassf1a promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008;14:3074–80.PubMedCrossRef
26.
Zurück zum Zitat Guo W, Dong ZM, Chen ZF, Yang ZB, Wen DG, Kuang G, et al. Aberrant cpg island hypermethylation of rassf1a in gastric cardia adenocarcinoma. Cancer Investig. 2009;27:459–65.CrossRef Guo W, Dong ZM, Chen ZF, Yang ZB, Wen DG, Kuang G, et al. Aberrant cpg island hypermethylation of rassf1a in gastric cardia adenocarcinoma. Cancer Investig. 2009;27:459–65.CrossRef
27.
Zurück zum Zitat Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol. 2009;40:1534–42.PubMedCrossRef Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. Hum Pathol. 2009;40:1534–42.PubMedCrossRef
28.
Zurück zum Zitat Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, et al. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta. 2012;413:787–94.PubMedCrossRef Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, et al. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta. 2012;413:787–94.PubMedCrossRef
29.
Zurück zum Zitat Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including runx3. Oncol Rep. 2007;18:1225–30.PubMed Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including runx3. Oncol Rep. 2007;18:1225–30.PubMed
30.
Zurück zum Zitat Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu BC, et al. Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer. 2013;13:259.PubMedCentralPubMedCrossRef Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu BC, et al. Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer. 2013;13:259.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2 Suppl 1:S4–S11.PubMedCrossRef Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2 Suppl 1:S4–S11.PubMedCrossRef
33.
Zurück zum Zitat Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123–7.PubMedCrossRef Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351:123–7.PubMedCrossRef
34.
35.
Zurück zum Zitat Wang J, Wang B, Chen X, Bi J. The prognostic value of rassf1a promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis. 2011;32:411–6.PubMedCrossRef Wang J, Wang B, Chen X, Bi J. The prognostic value of rassf1a promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis. 2011;32:411–6.PubMedCrossRef
36.
Zurück zum Zitat Gao T, Wang S, He B, Pan Y, Song G, Gu L, et al. The association of ras association domain family protein1a (rassf1a) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One. 2012;7:e48300.PubMedCentralPubMedCrossRef Gao T, Wang S, He B, Pan Y, Song G, Gu L, et al. The association of ras association domain family protein1a (rassf1a) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One. 2012;7:e48300.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of rassf1a promoter methylation in breast cancer: a meta-analysis of published data. PLoS One. 2012;7:e36780.PubMedCentralPubMedCrossRef Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of rassf1a promoter methylation in breast cancer: a meta-analysis of published data. PLoS One. 2012;7:e36780.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of rassf1a in head and neck cancer. Clin Cancer Res. 2003;9:3635–40.PubMed Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of rassf1a in head and neck cancer. Clin Cancer Res. 2003;9:3635–40.PubMed
Metadaten
Titel
Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis
verfasst von
Dong-Tao Shi
Mei Han
Nan Gao
Wenyan Tian
Weichang Chen
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1123-2

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.